Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684914 · ClinicalTrials.gov registry record · Phase 2
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
A Phase 2 study, sponsored by Altimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT04684914: Clinical Trial Phase 2 study, sponsored by Altimmune.
NCT04684914 is a Phase 2 study that was terminated before completion, run by Altimmune. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04684914, a Phase 2 study, was terminated before completion, sponsored by Altimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
Primary Outcome
Virologic response is defined as a 1.0-log reduction in quantitative hepatitis B surface antigen (HBsAg) or serologic clearance of HBsAg from Baseline to Day 169
Interventions
- DRUG Placebo
- BIOLOGICAL HepTcell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-12-26 |
| Est. Completion | 2024-04-17 |
| Phase | Phase 2 |
Why NCT04684914 stopped before completion
NCT04684914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04684914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04684914 about?
NCT04684914 is a clinical study titled "HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)". A study to evaluate the antiviral effects, immunogenicity, and safety of HepTcell in treatment-naive patients with inactive chronic hepatitis B (CHB) and low hepatitis B surface antigen (HBsAg) levels.
What is the current status of trial NCT04684914?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-12-26. Estimated completion is 2024-04-17.
What interventions are being tested in trial NCT04684914?
The interventions under investigation include: Placebo (DRUG), HepTcell (BIOLOGICAL).
Who is sponsoring clinical trial NCT04684914?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04684914's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI